undamentalytics Newsletter
Sign in

Quanterix Corp (QTRX) stock

Add to watchlist

Add holding +

NASDAQ: QTRX Nasdaq Life Sciences Tools & Services Next results ~November 9, 2026

C Fundamentals grade

Quanterix Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$4.4

Price-to-sales vs peers

Base case. Range ~$4.4–$22. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Quanterix Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling3 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds79 adding, 59 cuttingOf 28 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Quanterix files

Where Quanterix stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $153m, up 22.0% on a year earlier, faster than the 6.8% growth a quarter earlier. That growth ranks 3 of 31 among the life sciences tools & services companies we cover. Free-cash-flow margin fell to -53.2% from -26.1% a year earlier. Operating margin narrowed to -99.6% from -71.5%. The diluted share count is up 21.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $12.73 a share, against a share price of $3.16.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Quanterix Corp's trailing-twelve-month revenue grew 22.0% year on year, with a free-cash-flow margin of -53.2%. Where it stands out: change in growth rate of +15.1pp ranks 3 of 54 life sciences tools & services companies we cover. Where it lags: change in share count of 21.0% ranks 41 of 46 life sciences tools & services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 148.4% while net income fell 74.6%: a 74pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 22.0% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Growth speeding up. The growth rate is 15.1 points higher than a quarter earlier.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -99.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 28.1 points on a year ago.
  • Burning cash. Free cash flow was -53.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 21.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 92% and a beta of 1.9 against the S&P 500.
  • Gross margin slipping. Gross margin is down 10.7 points on a year ago.

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$1.04 against an average estimate of -$0.41: missed by 153.7%
Revenue
$33m, up 34.4% on a year earlier
Share reaction
-34.9% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 9, 2026

Quanterix's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.4%
  • 1 week+0.5%
  • 1 month-20.2%
  • This year-55.8%
  • 1 year-45.1%
  • 5 years-94.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$153M
Operating margin
-99.6%
Net margin
-80.2%
EPS (TTM, diluted)
$-2.63

Growth

Revenue growth
+22.0%
Change in growth rate
+15.1 pts
Share count change
+21.0%

Cash

Free cash flow (TTM)
-$81.7M
FCF margin
-53.2%
Stock pay % of revenue
12.1%

Earnings

Last results
August 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Quanterix Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Quanterix Corp as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$4.4 ~$6.0–$22 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$4.4 ~$4.4–$22 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Quanterix Corp with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201720182019202020212022202320242025Now
Share price$21.47$18.31$23.63$46.50$42.40$13.85$27.34$10.63$6.36$2.81
Market value$81m$403m$593m$1.4bn$1.5bn$512m$1.0bn$408m$271m$131m
+ Net debt (− = net cash)−$70m−$37m−$101m−$174m−$394m−$339m−$174m−$57m−$30m−$44m
Enterprise value$10m$366m$491m$1.2bn$1.1bn$174m$853m$351m$241m$87m
Multiples
Price / sales 3.5x10.7x10.5x15.9x13.8x4.9x8.4x3.0x2.0x0.9x
Price / earnings ——————————
Price / free cash flow ——————————
EV / EBITDA ——————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

18 /100

Weak moat

How hard Quanterix's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -9.7% of total assets over 8 years.

  • Pricing power 13 / 20

    Gross margin has been a median 51.3%, moving by 6.5 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -71.5%; its worst year was -99.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -53.2% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 39.8% over five years; stock-based pay has been a median 13.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (23 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $34m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.23 — $143m +3%
Next −$1.36 −11% $158m +10%

How the EPS forecast has moved

In the last 30 days, 0 analysts raised Quanterix Corp's forecast and 1 cut it.

Consensus EPS forecast Quanterix Corp, last 90 days
−$3.00 −$2.00 −$1.00 $0.00 60 days ago 30 days ago 7 days ago Now Current fiscal year, 60 days ago: −$2.08 Current fiscal year, 30 days ago: −$2.08 Current fiscal year, 7 days ago: −$2.08 Current fiscal year, Now: −$1.23 −$1.23 Next fiscal year, 60 days ago: −$1.91 Next fiscal year, 30 days ago: −$1.91 Next fiscal year, 7 days ago: −$1.91 Next fiscal year, Now: −$1.36 −$1.36

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
60 days ago −$2.08−$1.91
30 days ago −$2.08−$1.91
7 days ago −$2.08−$1.91
Now −$1.23−$1.36

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.41 −$1.04 −153.7%
Mar 2026 −$0.62 $0.16 +126.3%
Dec 2025 −$0.48 −$0.47 +2.1%
Sept 2025 −$0.53 −$0.73 −37.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy00%
Hold3100%
Sell00%

Monthly trend

  1. Oct 202633
  2. Sep 202633
  3. Aug 202633

Counts of recommendations published by analysts covering Quanterix Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.1%
of tradable shares
Days to cover
7.01
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
71%
of shares
Held by insiders
6.4%
of shares
Employees
450
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −47.4%

$5.34 on October 31, 2025 to $2.81

ThenNowEffect
Revenue (last 12 months) $126m $153m +22.0%
P/S multiple 1.6x 0.9x −47.8%
Share count 39m 47m −17.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −87.7%

$22.92 on November 3, 2023 to $2.81

ThenNowEffect
Revenue (last 12 months) $112m $153m +37.3%
P/S multiple 7.6x 0.9x −88.8%
Share count 37m 47m −20.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
QTRX−9%−67%+97%−61%−40%−56%
Industry peers (median)+5%−51%−3%−13%−2%+16%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
QTRX50%42%83%25%25%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
QTRX−59%−82%−32%−65%−65%−70%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 7, 2017: 97% from February 19, 2021 to August 10, 2026. Getting back needed a 3646% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.42 – $8.06
From 52-week high
−65.1%
vs 50-day average
−5.8%
vs 200-day average
−26.9%
Volatility (1 year)
92%
Beta vs S&P 500
1.95

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±14.5%
After a week
4 up, 8 down
typical move ±16.3%
After a month
2 up, 10 down
typical move ±24.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −34.9% −0.3% −27.5% −34.2%
May 6, 2026 −16.7% +1.1% −12.7% 0.0%
March 2, 2026 −10.4% −0.8% −22.1% −46.3%
January 8, 2026 +21.6% +0.7% +19.9% −6.9%
November 10, 2025 +1.2% +1.8% +11.9% +54.3%
August 7, 2025 −15.3% +0.7% −19.1% −19.4%
May 12, 2025 −12.1% +4.0% −7.8% +26.1%
March 17, 2025 +1.3% −0.3% +1.8% −24.1%
January 14, 2025 −5.4% +2.0% +10.0% −11.5%
January 10, 2025 −22.3% −1.4% −24.4% −32.8%
November 12, 2024 −19.0% −0.3% −27.8% −27.1%
August 8, 2024 −13.5% +2.8% −10.1% −5.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Quanterix Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Quanterix Corp
$110M $120M $130M $140M $150M $160M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $116.6M Revenue (TTM), FY23 Q4: $122.4M Revenue (TTM), FY24 Q1: $126M Revenue (TTM), FY24 Q2: $129.6M Revenue (TTM), FY24 Q3: $133.8M Revenue (TTM), FY24 Q4: $137.4M Revenue (TTM), FY25 Q1: $135.7M Revenue (TTM), FY25 Q2: $125.8M Revenue (TTM), FY25 Q3: $130.2M Revenue (TTM), FY25 Q4: $138.9M Revenue (TTM), FY26 Q1: $145M Revenue (TTM), FY26 Q2: $153.4M $153.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $116.6M
FY23 Q4 $122.4M
FY24 Q1 $126M
FY24 Q2 $129.6M
FY24 Q3 $133.8M
FY24 Q4 $137.4M
FY25 Q1 $135.7M
FY25 Q2 $125.8M
FY25 Q3 $130.2M
FY25 Q4 $138.9M
FY26 Q1 $145M
FY26 Q2 $153.4M
Revenue growth, TTM YoY Quanterix Corp
-10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 6.1% Revenue growth, TTM YoY, FY23 Q4: 16.0% Revenue growth, TTM YoY, FY24 Q1: 20.6% Revenue growth, TTM YoY, FY24 Q2: 16.0% Revenue growth, TTM YoY, FY24 Q3: 14.7% Revenue growth, TTM YoY, FY24 Q4: 12.3% Revenue growth, TTM YoY, FY25 Q1: 7.7% Revenue growth, TTM YoY, FY25 Q2: -2.9% Revenue growth, TTM YoY, FY25 Q3: -2.7% Revenue growth, TTM YoY, FY25 Q4: 1.1% Revenue growth, TTM YoY, FY26 Q1: 6.8% Revenue growth, TTM YoY, FY26 Q2: 22.0% 22.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 6.1%
FY23 Q4 16.0%
FY24 Q1 20.6%
FY24 Q2 16.0%
FY24 Q3 14.7%
FY24 Q4 12.3%
FY25 Q1 7.7%
FY25 Q2 -2.9%
FY25 Q3 -2.7%
FY25 Q4 1.1%
FY26 Q1 6.8%
FY26 Q2 22.0%
Operating margin (TTM) Quanterix Corp
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -46.1% Operating margin (TTM), FY23 Q4: -37.6% Operating margin (TTM), FY24 Q1: -40.1% Operating margin (TTM), FY24 Q2: -40.5% Operating margin (TTM), FY24 Q3: -38.5% Operating margin (TTM), FY24 Q4: -38.3% Operating margin (TTM), FY25 Q1: -47.0% Operating margin (TTM), FY25 Q2: -71.5% Operating margin (TTM), FY25 Q3: -88.8% Operating margin (TTM), FY25 Q4: -90.4% Operating margin (TTM), FY26 Q1: -96.9% Operating margin (TTM), FY26 Q2: -99.6% -99.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -46.1%
FY23 Q4 -37.6%
FY24 Q1 -40.1%
FY24 Q2 -40.5%
FY24 Q3 -38.5%
FY24 Q4 -38.3%
FY25 Q1 -47.0%
FY25 Q2 -71.5%
FY25 Q3 -88.8%
FY25 Q4 -90.4%
FY26 Q1 -96.9%
FY26 Q2 -99.6%
FCF margin (TTM) Quanterix Corp
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -17.3% FCF margin (TTM), FY23 Q4: -18.5% FCF margin (TTM), FY24 Q1: -26.5% FCF margin (TTM), FY24 Q2: -31.0% FCF margin (TTM), FY24 Q3: -31.4% FCF margin (TTM), FY24 Q4: -28.0% FCF margin (TTM), FY25 Q1: -24.3% FCF margin (TTM), FY25 Q2: -26.1% FCF margin (TTM), FY25 Q3: -52.4% FCF margin (TTM), FY25 Q4: -57.5% FCF margin (TTM), FY26 Q1: -57.2% FCF margin (TTM), FY26 Q2: -53.2% -53.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -17.3%
FY23 Q4 -18.5%
FY24 Q1 -26.5%
FY24 Q2 -31.0%
FY24 Q3 -31.4%
FY24 Q4 -28.0%
FY25 Q1 -24.3%
FY25 Q2 -26.1%
FY25 Q3 -52.4%
FY25 Q4 -57.5%
FY26 Q1 -57.2%
FY26 Q2 -53.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 18 23 38 57 86 111 106 122 137 139 153
Gross profit 8 10 18 27 48 65 45 74 83 65 65
EBITDA −21 −26 −30 −39 −27 −52 −99 −40 −46 −110 −129
Operating income −22 −26 −32 −42 −32 −57 −104 −46 −53 −126 −153
Net income −23 −27 −32 −41 −32 −56 −100 −28 −39 −107 −123
Diluted EPS — — — −$1.63 −$1.07 −$1.54 −$2.69 −$0.75 −$1.00 −$2.51 −$2.63
Growth (year on year)
Revenue — +30.1% +64.5% +50.8% +52.2% +28.0% −4.6% +16.0% +12.3% +1.1% +22.0%
Margins
Gross margin 44.1% 43.7% 47.7% 47.3% 55.8% 58.6% 43.0% 60.7% 60.5% 46.8% 42.7%
EBITDA margin −120.9% −111.6% −80.2% −68.0% −31.6% −46.7% −93.7% −32.5% −33.6% −79.0% −84.4%
Operating margin −123.5% −113.7% −83.8% −73.3% −36.6% −51.1% −98.8% −37.6% −38.3% −90.4% −99.6%
Net margin −131.8% −118.1% −83.8% −71.9% −36.5% −50.2% −94.4% −23.2% −28.0% −77.1% −80.2%
Free-cash-flow margin −103.9% −101.6% −80.4% −65.3% −31.6% −55.4% −57.1% −18.5% −28.0% −57.5% −53.2%
Cash flow
Cash from operations −18 −22 −29 −26 −23 −48 −49 −19 −35 −77 −81
Capital spending 1 1 2 11 4 14 12 4 3 3 1
Free cash flow −18 −23 −30 −37 −27 −61 −60 −23 −39 −80 −82
Stock-based pay 1 2 5 6 10 16 15 17 20 21 19
Free cash flow after stock pay −19 −25 −35 −43 −37 −77 −76 −40 −59 −101 −100
Balance sheet
Cash 30 80 44 109 182 396 339 174 57 30 44
Total debt 0 9 8 8 8 2 0 0 0 0 0
Net debt (negative = net cash) −30 −70 −37 −101 −174 −394 −339 −174 −57 −30 −44
Diluted shares 2m 4m 22m 25m 30m 36m 37m 38m 38m 43m 47m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $320m
Short-term assets $171mLonger-term assets $149m
What it owes, and who funded it · $320m
Short-term liabilities $50mLonger-term liabilities $32mShareholders' equity $237m
  • Short-term assets cover short-term liabilities $171m of assets due within a year against $50m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $171m short-term assets against $32m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Quanterix Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+21.0%
year over year
R&D spending
20.8%
of revenue
Sales & admin spending
85.6%
of revenue
Days sales outstanding
53 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated QTRX PACB GRAL CYRX CTKB MRVI Median
Revenue, last 12 months $153m $159m $165m $186m $207m $209m $229m
Revenue growth, last 12 months 22.0% 2.0% 23.1% 12.1% 5.4% −5.0% 6.9%
Revenue growth, 3-year average 11.1% 2.9% — −8.2% 5.6% −27.3% 2.9%
Revenue growth, latest quarter 34.4% −1.9% 25.7% 7.7% 5.6% 8.5% 8.5%
Gross margin 42.7% 36.4% — 47.1% 53.2% 34.9% 51.9%
Operating margin −99.6% −83.5% −338.4% −21.2% −21.6% −56.1% −14.3%
Operating margin, 3-year average −70.6% −250.8% <−999% −60.1% −16.1% −73.7% −22.4%
Net margin −80.2% −82.5% −236.9% −20.1% −39.0% −37.1% −16.1%
Cash from operations / revenue −52.7% −74.1% −178.4% 4.3% −2.9% −12.1% 1.3%
Free-cash-flow margin −53.2% −77.5% −179.2% −10.8% −5.9% −17.2% −2.2%
Free-cash-flow margin, 3-year average −36.8% −104.4% — −22.6% 1.7% −14.3% 0.6%
Stock pay / revenue 12.1% 21.5% 38.9% 5.2% 10.3% 14.3% 4.4%
Change in share count 21.0% 0.9% 18.5% 0.6% −0.3% 2.3% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 22.0% 6.9% 8 of 54
Change in growth rate Growth +15.1pp +0.4pp 3 of 54
Gross margin Profitability 42.7% 52.0% 32 of 45
Operating margin Profitability -99.6% -14.3% 41 of 52
Net margin Profitability -80.2% -12.2% 41 of 54
Free-cash-flow margin Cash generation -53.2% -1.3% 43 of 54
Stock pay as % of revenue Cash generation 12.1% 4.4% 37 of 53
Change in share count Balance sheet 21.0% 1.0% 41 of 46
Days sales outstanding Balance sheet 53 days 62 days 17 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $92.9M ▲ 16.6%
Consumable and Other Products $75.1M ▲ 8.4%
Simoa Product Revenue $71M ▼ 10.9%
Service and Other Revenue $44.2M ▼ 13.7%
Simoa Service and Other Revenue $32.4M ▼ 36.8%
Research Services $26M ▼ 31.6%
Spatial Product Revenue $21.9M —
Instrument Products $17.9M ▲ 70.4%
Spatial Service and Other Revenue $11.8M —
Service Type Warranties $11.1M ▲ 5.0%
Other Services $7.1M ▲ 168.6%
Licenses and services $1.5M ▼ 66.3%
Grant $243,000 ▼ 87.8%

These categories overlap or exclude eliminations, so shares aren't shown.

From Quanterix Corp's 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$139M
Institutions reporting
132
Shares held vs prior quarter
▼ 11.7%
Positions opened / closed
35 / 29

Top buyers and sellers, Q2 2026: 79 institutions bought and 59 sold ; the biggest buyer was First Eagle Investment Management, LLC (+4.2M shares) and the biggest seller Ameriprise Financial Inc (−2.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
First Eagle Investment Management, LLC $23.8M 5.5M 17.1% ▲ 323.5%
Blackrock, Inc. $15.7M 3.6M 11.3% ▲ 10.9%
Blue Water Life Science Advisors, LP $15M 3.5M 10.8% ▲ 62.2%
Portolan Capital Management, LLC $8.2M 1.9M 5.9% ▼ 35.5%
Vanguard Capital Management LLC $7.8M 1.8M 5.6% ▲ 0.9%
Lionhunter Capital Management, LLC $6.5M 1.5M 4.7% —
AQR Capital Management LLC $5.8M 1.3M 4.2% ▲ 1496.3%
Geode Capital Management, LLC $4.9M 1.1M 3.5% ▲ 13.7%
Ameriprise Financial Inc $4.3M 987K 3.1% ▼ 72.1%
Marshall Wace, LLP $4.2M 974K 3.0% ▲ 56.5%
State Street Corp $4M 932K 2.9% ▲ 3.8%
Tikvah Management LLC $2.5M 572K 1.8% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Quanterix Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $296,049 3 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $296,049 net buying
Insider Date Trade Shares Price Value
Donnelly William P Director August 13, 2026 Buy 72,245 $2.93 $211,678
Donnelly William P Director August 12, 2026 Buy 27,155 $2.75 $74,676
Meadows Benjamin Chief Commercial Officer May 12, 2026 Buy 3,500 $2.77 $9,695

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 10, 2026
  • May 6, 2026
  • March 2, 2026
  • January 8, 2026
  • November 10, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Quanterix Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Quanterix Corp in brief

What does Quanterix Corp do?
Quanterix Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Quanterix Corp's stock ticker?
Quanterix Corp trades under the ticker QTRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Quanterix Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Quanterix Corp reported revenue of $153M, 22.0% higher than a year earlier, according to its SEC filings.
What is Quanterix Corp's free cash flow?
Quanterix Corp's free-cash-flow margin is -53.2% of revenue over the trailing twelve months, ranking 43 of the 54 life sciences tools & services companies we cover.
Who are Quanterix Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are First Eagle Investment Management, LLC, Blackrock, Inc. and Blue Water Life Science Advisors, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Quanterix Corp's market cap?
On November 2, 2026, Quanterix Corp's market capitalisation was about $131M and net debt of -$44.2M. Market figures come from third-party market data and may be delayed.
Who are Quanterix Corp's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Quanterix Corp are Pacific Biosciences Of California, Inc., Grail, Inc., Cryoport, Inc., Cytek Biosciences, Inc. and Maravai Lifesciences Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Quanterix Corp's.
Are insiders buying or selling Quanterix Corp stock?
Over the last 12 months, Quanterix Corp's directors and officers reported 3 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Quanterix Corp's next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Quanterix Corp announces its own schedule.